Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.31 |
| ▸ | MTOR | P42345 | 3/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139671 | 0.83 | USP30 (0.39) | PIK3CAMTORHRH3OTUD7B | |
| SCHEMBL4130666 | 0.83 | BRD9 (0.40) | IDH1BRD9BRD7GRIA2ESR1 | |
| SCHEMBL4144552 | 0.82 | BRD9 (0.40) | IDH1BRD9BRD7GRIA2ESR1 | |
| SCHEMBL4136323 | 0.81 | IDH1 (0.39) | IDH1BRD9BRD7GRIA2ESR1 | |
| SCHEMBL4131005 | 0.81 | IDH1 (0.37) | IDH1BRD9BRD7GRIA2ESR1 | |
| SCHEMBL4152594 | 0.79 | IDH1 (0.36) | IDH1BRD9BRD7GRIA2PIK3CA | |
| SCHEMBL4773243 | 0.79 | BRD9 (0.39) | IDH1BRD9BRD7GRIA2ESR1 | |
| SCHEMBL4136350 | 0.79 | BRD9 (0.39) | IDH1BRD9BRD7GRIA2ESR1 | |
| SCHEMBL4139655 | 0.77 | IDH1 (0.46) | IDH1BRD9BRD7GRIA2PIK3CA | |
| SCHEMBL4128108 | 0.76 | CYP11B1 (0.38) | GRIA2OTUD7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | IDH1 4112/4885BRD9 4160/4885BRD7 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.